Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingfeijieduhuatan is a Traditional Chinese Medicine (TCM) granule formulation developed for the treatment of severe community-acquired pneumonia (CAP). It is specifically indicated for patients presenting with the 'phlegm-heat obstructing in the lung' syndrome. The drug is being evaluated in Phase 3 clinical trials by the Henan University of Traditional Chinese Medicine as part of an integrated medicine approach, where it is administered alongside conventional Western antibiotic therapy. Manufactured by Sanjiu Medical & Pharmaceutical Co., Ltd., the formulation is designed to clear pulmonary heat, neutralize toxins, and facilitate the resolution of phlegm to improve clinical outcomes in critically ill pneumonia patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingfeijieduhuatan.